Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2523-2530

  Mataga, Megan A ^a   Rosenthal, Shoshana ^a   Heerboth, Sarah ^a   Devalapalli, Amrita ^a   Kokolus, Shannon ^a   Evans, Leah R ^a   Longacre, Mckenna ^a   Housman, Genevieve ^a   Sarkar, Sibaji ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; ARHI; Breast cancer; Calpain; Cell cycle arrest; Combination therapy; HDAC; MCF 7 cells; MDA MB 231

Indexed keywords

APLASIA RAS HOMOLOG MEMBER I; CALPASTATIN; HISTONE DEACETYLASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTI BREAST CANCER EFFECT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL MDA MB 231; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL LINE; CELL STRAIN MCF 7; CELL SURVIVAL; CYTOTOXICITY TEST; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METHYLATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GLYCOPROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84865688852     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Curtis C, Shah S, Chin S-F, Turasvilli G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russel R, McKinney S, METABRIC Group, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L Ellis I, Purushotham A, Borresen-Dale A-L, Brenton JD, Tavare S, Caldas C and Aparicio S: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 10: 10983-10990, 2012.
2. Morrow PK and Hortobagyi GN: Management of breast cancer in the genome era. Annu Rev Med 60: 153-165, 2009.
3. Anders C and Carey LA: Understanding and treating triplenegative breast cancer. Oncology 22(11): 1233-1243, 2008.
4. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90(1): 85-94, 2012.
5. Frew AJ, Lindemann RK, Martin BP, Clarke CJP, Sharkey J, Anthony DA, Banks K-M, Haynes NM, Gangatirkar, Stanley K, Bolden J, Takeda K, Yagita H, Secrist JP, Smyth MJ and Johnstone RW: Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist: Proc Natl Acad Sci USA 105 (32): 11317-22, 2008
6. Sarkar S and Faller DV: T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 21(1): 47-53, 2011.
7. Gal-Yam EN, Saito Y, Egger G and Jones PA: Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59: 267-80, 2008. (Pubitemid 351287937)
8. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa J-PJ, Bast RC Jr. and Yu Y: Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 12(15): 1791-800, 2003. (Pubitemid 36944134)
9. Miyazaki T, Honda K, and Ohata H: Requirement of Ca2+ influx- and phosphatidylinositol-3-kinase-mediated m-calpain activity for shear stress-induced endothelial cell polarity. Am J Physiol Cell Physiol 293(4): C1216-1225, 2007. (Pubitemid 47556733)
10. Storr SJ, Carragher NO, Frame MC, Parr, T and Martin SG: The calpain system and cancer. Nat Rev Cancer 11(5): 364-74, 2011.
11. Sarkar S, Loew JE, Forman LW, Perrine SP, and Faller DV: Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 31: 2723-732, 2011.
12. Sarkar S, Svoboda M, De-Beaumont R, and Freedman A: The role of AKT and RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma 43(8): 1663-1671, 2002. (Pubitemid 34823488)
13. Sarkar S: Platelets related to thrombosis and fibrinolysis. Clin Lipidol 2(5S): 596, 2008.
14. Sarkar S, Freedman J and Varghese S: Methods for Treating Thrombosis: Methods for sustaining eNOS activity. Publication Number: US2011/0124512A1, US Patent Application (PCT) Filed, 2010.
15. Mani SK, Balasubramanian S, Zavadzkas J, Jeffords LB, Rivers WT, Zile MR, Mukherjee R, Spinale FG and Kuppuswamy D: Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol 297 (5): 1744-1751, 2009.